S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
Log in

NASDAQ:ARDXArdelyx Stock Price, Forecast & News

$5.61
-0.07 (-1.23 %)
(As of 08/14/2020 04:00 PM ET)
Add
Compare
Today's Range
$5.58
Now: $5.61
$5.73
50-Day Range
$5.58
MA: $6.35
$7.07
52-Week Range
$2.10
Now: $5.61
$8.81
Volume321,751 shs
Average Volume754,099 shs
Market Capitalization$500.08 million
P/E RatioN/A
Dividend YieldN/A
Beta1.88
Ardelyx, Inc., a biopharmaceutical company, develops and sells medicines for the treatment of cardiorenal diseases in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase 3 clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase 3 clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. It also develops RDX013, a small molecule potassium secretagogue program for the treatment of patients with hyperkalemia. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was founded in 2007 and is headquartered in Fremont, California.
Read More
Ardelyx logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.57 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ARDX
CUSIPN/A
Phone510-745-1700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$5.28 million
Book Value$1.64 per share

Profitability

Net Income$-94,940,000.00
Net Margins-1,090.69%

Miscellaneous

Employees88
Market Cap$500.08 million
Next Earnings Date11/4/2020 (Estimated)
OptionableOptionable
$5.61
-0.07 (-1.23 %)
(As of 08/14/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ARDX News and Ratings via Email

Sign-up to receive the latest news and ratings for ARDX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Ardelyx (NASDAQ:ARDX) Frequently Asked Questions

How has Ardelyx's stock price been impacted by COVID-19?

Ardelyx's stock was trading at $5.98 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ARDX shares have decreased by 6.2% and is now trading at $5.61.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Ardelyx?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ardelyx in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Ardelyx
.

When is Ardelyx's next earnings date?

Ardelyx is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Ardelyx
.

How were Ardelyx's earnings last quarter?

Ardelyx Inc (NASDAQ:ARDX) announced its quarterly earnings data on Thursday, August, 6th. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.27) by $0.01. Ardelyx had a negative net margin of 1,090.69% and a negative return on equity of 65.94%.
View Ardelyx's earnings history
.

What price target have analysts set for ARDX?

5 analysts have issued 12-month price objectives for Ardelyx's shares. Their forecasts range from $9.00 to $15.00. On average, they expect Ardelyx's stock price to reach $12.00 in the next twelve months. This suggests a possible upside of 113.9% from the stock's current price.
View analysts' price targets for Ardelyx
.

Has Ardelyx been receiving favorable news coverage?

News articles about ARDX stock have been trending somewhat negative on Friday, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Ardelyx earned a news impact score of -1.3 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future.
View the latest news about Ardelyx
.

Are investors shorting Ardelyx?

Ardelyx saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 5,440,000 shares, an increase of 68.9% from the June 15th total of 3,220,000 shares. Based on an average daily trading volume, of 769,100 shares, the days-to-cover ratio is presently 7.1 days.
View Ardelyx's Short Interest
.

Who are some of Ardelyx's key competitors?

What other stocks do shareholders of Ardelyx own?

Who are Ardelyx's key executives?

Ardelyx's management team includes the following people:
  • Mr. Michael G. Raab, Pres, CEO & Director (Age 55, Pay $988k)
  • Ms. Elizabeth A. Grammer, Chief Legal & Admin. Officer and Sec. (Age 56, Pay $596k)
  • Mr. David Rosenbaum, Chief Devel. Officer (Age 59, Pay $617.25k)
  • Mr. Keith Santorelli, Acting Principal Financial & Accounting Officer (Age 46)
  • Mr. Jeffrey W. Jacobs, Chief Scientific Officer (Age 57)

What is Ardelyx's stock symbol?

Ardelyx trades on the NASDAQ under the ticker symbol "ARDX."

Who are Ardelyx's major shareholders?

Ardelyx's stock is owned by a number of institutional and retail investors. Top institutional shareholders include NEA Management Company LLC (15.33%), Vanguard Group Inc. (4.05%), Marshall Wace LLP (3.71%), Ikarian Capital LLC (1.56%), Goldman Sachs Group Inc. (0.74%) and Bailard Inc. (0.52%). Company insiders that own Ardelyx stock include David M Mott, David P Rosenbaum, Elizabeth A Grammer, Forest Baskett, Mark Kaufmann, Michael Raab and Scott D Sandell.
View institutional ownership trends for Ardelyx
.

Which major investors are selling Ardelyx stock?

ARDX stock was sold by a variety of institutional investors in the last quarter, including NEA Management Company LLC, EAM Investors LLC, FMR LLC, Ikarian Capital LLC, Goldman Sachs Group Inc., Bailard Inc., Marshall Wace LLP, and Strs Ohio. Company insiders that have sold Ardelyx company stock in the last year include Elizabeth A Grammer, Forest Baskett, Mark Kaufmann, Michael Raab, and Scott D Sandell.
View insider buying and selling activity for Ardelyx
.

Which major investors are buying Ardelyx stock?

ARDX stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Teacher Retirement System of Texas, Swiss National Bank, Alps Advisors Inc., Hamilton Lane Advisors LLC, Principal Financial Group Inc., California Public Employees Retirement System, and Bank of New York Mellon Corp.
View insider buying and selling activity for Ardelyx
.

How do I buy shares of Ardelyx?

Shares of ARDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Ardelyx's stock price today?

One share of ARDX stock can currently be purchased for approximately $5.61.

How big of a company is Ardelyx?

Ardelyx has a market capitalization of $500.08 million and generates $5.28 million in revenue each year. The biopharmaceutical company earns $-94,940,000.00 in net income (profit) each year or ($1.47) on an earnings per share basis. Ardelyx employs 88 workers across the globe.

What is Ardelyx's official website?

The official website for Ardelyx is www.ardelyx.com.

How can I contact Ardelyx?

Ardelyx's mailing address is 34175 ARDENWOOD BOULEVARD SUITE 200, FREMONT CA, 94555. The biopharmaceutical company can be reached via phone at 510-745-1700 or via email at [email protected]

This page was last updated on 8/14/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.